304 related articles for article (PubMed ID: 21050467)
1. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules.
Teschendorff AE; Gomez S; Arenas A; El-Ashry D; Schmidt M; Gehrmann M; Caldas C
BMC Cancer; 2010 Nov; 10():604. PubMed ID: 21050467
[TBL] [Abstract][Full Text] [Related]
2. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.
Teschendorff AE; Miremadi A; Pinder SE; Ellis IO; Caldas C
Genome Biol; 2007; 8(8):R157. PubMed ID: 17683518
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
Wirapati P; Sotiriou C; Kunkel S; Farmer P; Pradervand S; Haibe-Kains B; Desmedt C; Ignatiadis M; Sengstag T; Schütz F; Goldstein DR; Piccart M; Delorenzi M
Breast Cancer Res; 2008; 10(4):R65. PubMed ID: 18662380
[TBL] [Abstract][Full Text] [Related]
4. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
[TBL] [Abstract][Full Text] [Related]
5. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
6. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
[TBL] [Abstract][Full Text] [Related]
7. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
García Fernández A; Giménez N; Fraile M; González S; Chabrera C; Torras M; González C; Salas A; Barco I; Cirera L; Cambra MJ; Veloso E; Pessarrodona A
Breast; 2012 Jun; 21(3):366-73. PubMed ID: 22487206
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
9. Molecular classification of estrogen receptor-positive/luminal breast cancers.
Geyer FC; Rodrigues DN; Weigelt B; Reis-Filho JS
Adv Anat Pathol; 2012 Jan; 19(1):39-53. PubMed ID: 22156833
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
[TBL] [Abstract][Full Text] [Related]
11. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive profiling of biological processes reveals two major prognostic subtypes in breast cancer.
Chen F; Gao S; Wang F; Ma J; Zhang M; Lv M; Zhou Q; Fu Z; Lu C; Yin H
Tumour Biol; 2016 Mar; 37(3):3365-70. PubMed ID: 26446459
[TBL] [Abstract][Full Text] [Related]
13. Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.
Izadi P; Mehrdad N; Foruzandeh F; Reza NM
Asian Pac J Cancer Prev; 2012; 13(8):4113-7. PubMed ID: 23098526
[TBL] [Abstract][Full Text] [Related]
14. Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores.
Hu T; Chen Y; Liu Y; Zhang D; Pan J; Long M
BMC Med Res Methodol; 2021 May; 21(1):108. PubMed ID: 34022815
[TBL] [Abstract][Full Text] [Related]
15. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
16. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Rody A; Holtrich U; Pusztai L; Liedtke C; Gaetje R; Ruckhaeberle E; Solbach C; Hanker L; Ahr A; Metzler D; Engels K; Karn T; Kaufmann M
Breast Cancer Res; 2009; 11(2):R15. PubMed ID: 19272155
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers.
Hong CC; Yao S; McCann SE; Dolnick RY; Wallace PK; Gong Z; Quan L; Lee KP; Evans SS; Repasky EA; Edge SB; Ambrosone CB
Breast Cancer Res Treat; 2013 Jun; 139(2):477-88. PubMed ID: 23624818
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome.
Umemura S; Shirane M; Takekoshi S; Kusakabe T; Itoh J; Egashira N; Tokuda Y; Mori K; Osamura YR
Br J Cancer; 2009 Mar; 100(5):764-71. PubMed ID: 19259095
[TBL] [Abstract][Full Text] [Related]
19. Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.
Datta J; Fracol M; McMillan MT; Berk E; Xu S; Goodman N; Lewis DA; DeMichele A; Czerniecki BJ
JAMA Oncol; 2016 Feb; 2(2):242-6. PubMed ID: 26719971
[TBL] [Abstract][Full Text] [Related]
20. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
Desmedt C; Haibe-Kains B; Wirapati P; Buyse M; Larsimont D; Bontempi G; Delorenzi M; Piccart M; Sotiriou C
Clin Cancer Res; 2008 Aug; 14(16):5158-65. PubMed ID: 18698033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
